Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
10:06:55 EDT Fri 03 Oct 2025
Enter Symbol
or Name
USA
CA



Q:ATOS - ATOSSA THERAPEUTICS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
ATOS - Q0.70.9491·0.952.90.947+0.0272.9258.2234950.93  0.947  0.92211.66  0.552609:48:01Oct 0115 min RT 2¢

Recent Trades - Last 10 of 95
Time ETExPriceChangeVolume
09:48:06Q0.94980.029850
09:48:01Q0.94970.029748
09:47:24Q0.94690.0269500
09:47:24Q0.9470.027200
09:47:24Q0.94910.02915
09:47:20Q0.9470.027787
09:46:42Q0.94690.0269250
09:45:36Q0.94690.02691,359
09:45:30Q0.94670.0267400
09:45:20Q0.9470.027500

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-10-01 08:30U:ATOSNews ReleaseAtossa Therapeutics Names Janet R. Rea, MSPH, as Senior Vice President, R&D to Accelerate (Z)-Endoxifen Toward Key Regulatory Milestones
2025-09-17 08:00U:ATOSNews ReleaseAtossa Therapeutics Appoints CORE IR for Investor Relations, Shareholder Communications and Public Relations Services
2025-09-08 08:30U:ATOSNews ReleaseAtossa Therapeutics Announces Regulatory Strategy Aimed at Accelerating Development of Low-Dose (Z)-Endoxifen for Breast Cancer Risk Reduction
2025-08-28 08:30U:ATOSNews ReleaseAtossa Therapeutics CEO to Discuss Clinical Progress and Upcoming Milestones at 27th Annual H.C. Wainwright Global Investment Conference
2025-08-20 08:30U:ATOSNews ReleaseAtossa Therapeutics Selects PSI as Contract Research Organization for Pivotal Dose-Ranging Study of (Z)-Endoxifen in Metastatic Breast Cancer
2025-08-12 08:30U:ATOSNews ReleaseAtossa Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Corporate Update
2025-07-29 07:45U:ATOSNews ReleaseAtossa Therapeutics Announces Positive FDA Feedback, Advances Toward IND for (Z)-Endoxifen Clinical Program in ER+/HER2- Metastatic Breast Cancer
2025-06-02 08:45U:ATOSNews ReleaseAtossa Therapeutics to Present at the Jefferies Global Healthcare Conference
2025-05-20 09:02U:ATOSNews ReleaseJoin Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22
2025-05-14 08:15U:ATOSNews ReleaseAtossa Therapeutics Announces Full Results from I-SPY2 Endocrine-Optimization Sub-Study Evaluating Low-Dose (Z)-Endoxifen
2025-05-13 08:00U:ATOSNews ReleaseAtossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update
2025-04-30 08:45U:ATOSNews ReleaseAtossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio
2025-04-29 08:45U:ATOSNews ReleaseAtossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025
2025-04-22 08:45U:ATOSNews ReleaseAtossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio
2025-04-10 08:00U:ATOSNews ReleaseNona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer
2025-03-25 08:00U:ATOSNews ReleaseAtossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update
2025-03-20 09:13U:ATOSNews ReleaseAtossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
2025-03-11 08:15U:ATOSNews ReleaseAtossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications
2025-02-05 08:00U:ATOSNews ReleaseAtossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care
2025-01-30 08:17U:ATOSNews ReleaseAtossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No. 12,201,591